Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer

ABSTRACT: The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study. Secondary objectives include the evaluation of overall objective response rate to treatment, progression-free survival, overall survival, safety and documentation of potential immunogenicity of aflibercept. This study was a non-comparative randomized trial and was not powered for a comparison of any of the efficacy endpoints. Rather, the aim of the trial was to get, for all endpoints, an estimation of the efficacy and safety of aflibercept combined with a modified FOLFOX6 regimen. In such type of non-comparative randomized trial, the control FOLFOLX6 arm was intended to only act as a check on the similarity of the current patients to the historical controls with respect to clinical outcome when given FOLFOX6 treatment.

DISEASE(S): Metastatic Colorectal Cancer,Neoplasm Metastasis,Colon Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms,Neoplasms

PROVIDER: 2068501 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

cLoops2: a full-stack comprehensive analytical tool for chromatin interactions

Project description:Investigating chromatin interactions between regulatory regions such as enhancer and promoter elements is pivotal for a deeper understanding of gene expression regulation. The emerging 3D mapping technologies focusing on enriched signals such as Hi-TrAC/Trac-looping and HiChIP, compared to Hi-C, reduce the sequencing cost, and provide higher interaction resolution for cis-regulatory elements and more comprehensive information such as chromatin accessibility. A robust pipeline is needed for the comprehensive interpretation of these data, especially for loop-centric analysis. Therefore, we have developed a new versatile tool named cLoops2 for the full-stack analysis of the 3D chromatin interaction data. cLoops2 consists of core modules of peak-calling, loop-calling, differentially enriched loops calling and loops annotation. Additionally, it also contains multiple modules to carry out interaction resolution estimation, data similarity estimation, features quantification and aggregation analysis, and visualization. cLoops2 with documentation and example data are open source and freely available at GitHub: https://github.com/YaqiangCao/cLoops2

2021-11-29 | GSE179010 | GEO

LICC: L-BLP25 in Patients with Colorectal Cancer after resection of liver metastases - a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial

Project description:Primary objectives: Comparative evaluation of recurrence-free survival time and three year overall survial between the treatment groups L-BLP25 plus cyclophosphamide versus placebo vaccination and saline infusion Primary endpoints: Recurrence-Free Survival (RFS) time and three year overall survival based on standard imaging.

| 2529185 | ecrin-mdr-crc

Survival in colorectal patients in a tertiary care centre.

Project description:Primary outcome(s): 1.Estimation of overall survival (OS) rate and median overall survival of colorectal cancer treated patientsTimepoint: 1 month

| 2585626 | ecrin-mdr-crc

Identification of expression quantitative trait loci (eQTL) in human liver (SNP)

Project description:We genotyped 149 human surgical liver samples from Caucasian donors with detailed medical documentation. The overall purpose of the study was to identify expression quantitative trait loci (eQTL) in human liver.....

2012-07-03 | GSE39036 | GEO

Identification of expression quantitative trait loci (eQTL) in human liver

Project description:We performed genome-wide mRNA profiling of 149 human surgical liver samples from Caucasian donors with detailed medical documentation. The overall purpose of the study was to identify expression quantitative trait loci (eQTL) in human liver.

2011-10-10 | GSE32504 | GEO

Expression profiling of mouse liver after treatment with Vascular Endothelial Growth Factor (VEGF) inhibitor aflibercept

Project description:Transcriptional profiling of mouse liver was compared between VEGF inhibitor aflibercept and control treatment after 9 weeks. 8-10 week-old SCID mice received VEGF Trap protein (aflibercept) subcutaneously twice per week at 25mg per kg body weight for 9 weeks. For control groups, mice were treated with humanized Fc (Regeneron). 5 biological replicates were performed for the control group and 4 biological replicates were performed for the treatment group

2013-09-01 | E-GEOD-50519 | biostudies-arrayexpress

Study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with metastatic colorectal cancer after failure of an oxaliplatin-based regimen

Project description:Primary objectives: To assess the non inferiority of aflibercept + 5FU/LV as maintenance vs aflibercept+ FOLFIRI with progression free survival (PFS) as the primary outcome parameterin elderly patients (≥70 years). Primary endpoints: Progression-free survival

| 2536279 | ecrin-mdr-crc

Expression profiling of mouse liver after treatment with Vascular Endothelial Growth Factor (VEGF) inhibitor aflibercept

Project description:Transcriptional profiling of mouse liver was compared between VEGF inhibitor aflibercept and control treatment after 9 weeks.

2013-09-01 | GSE50519 | GEO

Pseudogenes limit the identification of novel common transcripts generated by their parent genes

Project description:Genomic sequences with high sequence similarity, such as parent-pseudogene pairs, cause short sequencing reads to align to multiple locations, thus complicating genomic analyses. However, their impact on transcriptomic analyses, including the estimation of gene expression and transcript annotation, has been less studied. Here, we investigated the impact of pseudogenes on transcriptomic analyses.

2022-10-15 | GSE215459 | GEO

Study to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphisms

Project description:Primary objectives: To evaluate the efficacy of FOLFIRI + aflibercept in patients with or without ACE polymorphisms in terms of progression-free survival (PFS) Primary endpoints: Progression-free survival

| 2535685 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data